文献速递脑血管病认知障碍与痴呆

房颤患者华法林与四种直接口服抗凝药痴呆风险比较

Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation.
PubMed 文献 · Stroke · 2021-09-09

共纳入72 846例患者,华法林组25 948例,DOAC组46 898例。总体DOAC与华法林痴呆风险相当,但在65-74岁或既往卒中患者中DOAC风险更低,仅依度沙班与较低痴呆风险相关。

要点

  • 总体DOAC与华法林痴呆风险相当。
  • 65-74岁患者DOAC痴呆风险低于华法林(HR 0.815)。
  • 既往卒中患者DOAC痴呆风险低于华法林(HR 0.891)。

核心结论

  • 在大型亚洲房颤人群中,DOAC总体痴呆风险与华法林相当。
  • DOAC在65-74岁或既往卒中患者中可能比华法林更有益。
  • 特定DOAC中仅依度沙班与较低痴呆风险相关。

研究设计与样本

  • 纳入口服抗凝药初治的非瓣膜性房颤患者,年龄≥40岁。
  • 华法林组与DOAC组采用逆概率治疗加权法平衡。
  • 共72 846例患者,华法林组25 948例,DOAC组46 898例。

主要发现

  • 随访平均1.3±1.1年,痴呆粗发生率为4.87/100人年。
  • 血管性痴呆粗发生率为1.20/100人年,阿尔茨海默病痴呆为3.30/100人年。
  • DOAC与华法林相比痴呆、血管性痴呆和阿尔茨海默病痴呆风险相当。
  • 65-74岁患者DOAC痴呆风险低于华法林(HR 0.815 [95%CI 0.709–0.936])。
  • 既往卒中患者DOAC痴呆风险低于华法林(HR 0.891 [95%CI 0.820–0.968])。

临床怎么用

  • 房颤抗凝选择时,总体痴呆风险DOAC与华法林相当。
  • 对65-74岁或既往卒中房颤患者,可优先考虑DOAC以降低痴呆风险。
  • 特定DOAC中依度沙班与较低痴呆风险相关,可作为个体化选择参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Atrial fibrillation is a risk factor for dementia, and oral anticoagulant use is associated with a decreased risk of dementia in patients with atrial fibrillation. We aimed to investigate whether the risk of dementia would be different between patients treated with direct oral anticoagulants (DOACs) compared with those with warfarin. METHODS: Using the Korean nationwide claims database from January 2014 to December 2017, we identified oral anticoagulant–naive nonvalvular atrial fibrillation patients aged ≥40 years. For the comparisons, warfarin and DOAC groups were balanced using the inverse probability of treatment weighting method. The primary outcome was incident dementia. RESULTS: Among 72 846 of total study patients, 25 948 were treated with warfarin, and 46 898 were treated with DOAC (17 193 with rivaroxaban, 9882 with dabigatran, 11 992 with apixaban, and 7831 with edoxaban). During mean 1.3±1.1 years of follow-up, crude incidence of dementia was 4.87 per 100 person-years (1.20 per 100 person-years for vascular dementia and 3.30 per 100 person-years for Alzheimer dementia). Compared with warfarin, DOAC showed a comparable risks of dementia, vascular dementia, and Alzheimer dementia. In subgroup analyses, DOAC was associated with a lower risk of dementia than warfarin, particularly in patients aged 65 to 74 years (hazard ratio, 0.815 [95% CI, 0.709–0.936]) and in patients with prior stroke (hazard ratio, 0.891 [95% CI, 0.820–0.968]). When comparing individual DOACs with warfarin, edoxaban was associated with a lower risk of dementia (hazard ratio, 0.830 [95% CI, 0.740–0.931]). CONCLUSIONS: In this large Asian population with atrial fibrillation, DOAC showed a comparable risk of dementia with warfarin overall. DOACs appeared more beneficial than warfarin, in those aged 65 to 74 years or with a history of stroke. For specific DOACs, only edoxaban was associated with a lower risk of dementia than warfarin.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lee SR, Choi EK, Park SH, et al. Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation. Stroke. 2021. PMID: 34496627. doi:10.1161/STROKEAHA.120.033338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。